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S urvival in symptomatic severe aortic stenosis(AS) is dismal without either transcatheteraortic valve replacement (TAVR) or surgical
aortic valve replacement. It is also now well recog-
nized that symptoms in individuals with severe AS
may be unreliable and there is increasing evidence
that, even in cases of truly asymptomatic severe AS,
there are factors which constitute very severe AS (1).
The 2-year event-free survival of untreated asymp-
tomatic very severe AS is w40% (compared to
w70% for asymptomatic severe AS). Therefore, those
patients with low surgical risk with very severe AS
may benefit from AVR, even in the absence of symp-
toms. There are large randomized studies (AVATAR
[Aortic Valve Replacement Versus Conservative
Treatment in Asymptomatic Severe Aortic Stenosis],
EVoLVeD [Early Valve Replacement Guided by Bio-
markers of Left Ventricular Decompensation in
Asymptomatic Patients with Severe AS], ESTIMATE
[Early Surgery for Patients with Asymptomatic
Aortic Stenosis], and EARLY-TAVR [Evaluation of
Transcatheter Aortic Valve Replacement Compared
to SurveilLance for Patients with AsYmptomatic
Severe Aortic Stenosis]) underway to assess the effi-
cacy and safety of early TAVR versus conservative
management in cases of asymptomatic severe AS,
the results of which will perhaps help us move awayISSN 0735-1097/$36.00
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AVR in severe AS (2).In this issue of the Journal, Strange et al. (3) pro-
vide short- and long-term clinical outcome findings in
241,303, individuals identified from the National
Echocardiography Data of Australia (NEDA) as having
either no AS, mild AS, moderate or severe AS. Aortic
valve maximum velocity (Vmax) and mean gradient
(MG) were used to categorize these patients, except
for those with a stroke volume index (SVi) <35 ml/m2
when calculated aortic valve area (AVA) was used to
classify AS. Patients with no AS (n ¼ 215,476;
MG: <10 mm Hg; Vmax: <2.0 m/s) and those with
mild AS (n ¼ 16,129; MG: 10 to 20 mm Hg; Vmax: 2.0 to
3.0 m/s) had similar survival rates at 1 and 5 years.
Patients with high- or low-gradient severe AS
(n ¼ 6,383; MG: >40 mm Hg; Vmax: >4.0 m/s; or
AVA: <1.0 cm2) had a 3-fold increase in mortality over
the same period, which confirms what is known.
However, the most intriguing finding was that the
mortality rate in patients with moderate AS (n ¼ 3,315;
Vmax: 3.0 to 4.0 m/s; and MG: 20 to 30 mm Hg) was
similar to that in those with severe AS. In fact, the
data suggest that a Vmax of >3 m/s or a MG of
>20 mm Hg was the inflection point at which there
was a 2-fold increase in mortality compared to that in
patients with mild AS. This was true even when sex,
age, SVi, left ventricle ejection fraction (LVEF), and
the presence of aortic regurgitation were taken into
consideration.
Thus, is moderate AS not a benign stage in the
evolution of the disease as the conventional wisdom
tells us? The answer is as complex as it is unclear, but
it would be a folly to dismiss these provocative find-
ings as mere technical errors in the Doppler echocar-
diographic data. There is no question that suboptimal
Doppler echocardiographic in AS is often the source of
inconsistent grading of the severity of AS. However,https://doi.org/10.1016/j.jacc.2019.08.1029
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Red indicates conservative (follow-up) management. Yellow indicates no evidence yet for intervention, but ongoing trials will be instructive. Green represents current
guideline-based indications for intervention in AS. *PET imaging. †BNP, myocardial stretch/volume status; troponin, myocardial injury; soluble ST2, myocardial
remodeling; acylcarnitines, myocardial metabolic distress; cBIN1, cardio myocyte remodeling. AoV ¼ aortic valve; AS ¼ aortic stenosis; AVATAR ¼ Aortic Valve
Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis; AVR ¼ aortic valve replacement; BNP ¼ B-type natriuretic peptide;
cBIn1 ¼ cardiac bridging integrator 1; EARLY-TAVR ¼ Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients with AsYmp-
tomatic Severe Aortic Stenosis; ESTIMATE ¼ Early Surgery for Patients with Asymptomatic Aortic Stenosis; EVoLVeD ¼ Early Valve Replacement Guided by Biomarkers
of Left Ventricular Decompensation in Asymptomatic Patients with Severe AS; GLS ¼ global longitudinal strain; Lp (a) ¼ lipoprotein (a); LV ¼ left ventricle; LVEF ¼ left
ventricle ejection fraction; MG ¼ mean gradient; PA ¼ pulmonary artery; PAP ¼ pulmonary artery pressure; PET ¼ positron emission tomography; RECOVERY ¼ Early
Surgery Versus Conventional Treatment in Very Severe Aortic Stenosis; sST2 ¼ soluble suppression of tumorigenicity-2; SV ¼ stroke volume; TAPSE ¼ tricuspid
annular plane systolic excursion; TAVR UNLOAD ¼ Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure;
Vmax ¼ aortic valve maximum velocity.
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1865the authors of the NEDA data recognize and
acknowledge this. They have used Doppler velocity
data for the most part and resorted to AVA, which
involves measurement of left ventricular outflowtract diameter, the most common source of error in
computation of AVA only when SVi was reduced.
Also, they used dimensionless index (DI) to analyze
the data and came to the same conclusion: patients
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1866with DI 0.25 to 0.30 (moderate AS) demonstrated
short- and long-term event dates similar to those with
DI <0.25 (severe AS). Then there are limitations of
observational data such as the lack of information
about comorbid factors, which may have influenced
the outcomes, or that many individuals with moder-
ate AS might have progressed to severe AS since their
last echocardiogram. Notwithstanding these limita-
tions, the observation that moderate AS is not
necessarily a benign condition has been made before.
Chizner et al. (4) showed that 6 of the 10 patients with
cardiac catheterization determined to have moderate
AS (AVA: 0.71 to 1.09 cm2) and peak aortic valve
gradient <70 mm Hg died within 9 months after the
diagnosis. Data from the study by Kennedy et al. (5)
showed that, in those with AVA 0.7 to 1.2 cm2 (clas-
sified as moderate AS), the 4-year event-free survival
was only 59%, even in the absence of symptoms (or
minimally symptomatic) or dysfunction. The pres-
ence of symptoms or LVEF <50% in these patients
worsened the outcome. Also, the presence of coro-
nary artery disease had no demonstrable effect on AS-
related events. It is possible that some of the patients
in these 2 studies had severe AS based on the current
definition based on AVA, which is <1 cm2. However,
at normal flow rates, a MG of 40 mm Hg (one of the
indices for severe AS) is usually reached only when
the AVA is reduced to w0.8 cm2, which is similar to
the threshold the authors used to differentiate mod-
erate from severe AS in these 2 studies. There are also
more contemporary data (6) which all confirm these
findings in moderate AS. More recently, data from
Van Gils et al. (7). and Lancellotti et al. (8) showed
higher adverse event rates in moderate AS (using the
current Doppler echocardiographic definition) than in
those with LVEF <50% and an age-matched popula-
tion with mild AS, respectively.
How do we interpret and what are the implications
of these data for moderate AS? These data may prompt
reconsideration of the current time-honored approach
of classifying AS as mild, moderate, and severe using
Doppler echocardiographic data. This approach by its
nature implies that the assessment of the degree of AS
is relevant to that single point of assessment of the
valve and that Doppler hemodynamics are by them-
selves not sufficient to fully characterize the disease
severity. The under-recognition and undertreatment
of severe AS, which is said to be as high as w70% in
some estimates,may in fact be due in no smallmeasure
to over-reliance on such firm categorization of AS
based on Doppler echocardiographic data alone. The
challenge is to consider a less dogmatic approach by
staging the disease instead of classifying the disease
based solely on valve hemodynamics. Recentdescriptions of staging AS using multiple cardiac and
noncardiac factors are instructive and thought pro-
voking (9,10). The composite evaluation of risk using
such a staging method puts the focus on the disease
rather than on isolated factors. This may move the
needle toward timely and earlier intervention in AS to
potentially fully reverse the adverse cardiac effects of
AS after intervention (8). Integration of myocardial
structural changes (fibrosis and scar assessment by
cardiac magnetic resonance imaging) and more sensi-
tive indices of myocardial dysfunction (strain mea-
surements using speckle tracking echocardiography)
in the staging of AS will further refine the utility of
these schemes. Advances in the identification of bio-
markers which signal not only myocardial injury or
stress (troponin, N-terminal pro–B-type natriuretic
peptide concentrations) (2) but metabolomic markers
(11), which indicate myocardial metabolic distress, will
surely aid in further refining the staging of the disease.
Finally, biomarkers such as lipoprotein(a) and
oxidized phospholipids (OxPL) indicate disease activ-
ity in the valve. These are exciting new frontiers, which
not only allow staging the disease but can predict
progression (12). Furthermore, they provide a tool for
surveillance and are potential treatment targets for
slowing disease progression. When analyzed collec-
tively, these findings raise the hypothesis that early
AVR is beneficial in patients with moderate AS at an
advanced stage of cardiac damage and high risk of
rapid progression of AS. This hypothesis is currently
being tested in the TAVR-UNLOAD (Transcatheter
Aortic Valve Replacement to UNload the Left Ventricle
in Patients With ADvanced Heart Failure) trial which
compares TAVR with medical management in patients
with moderate AS and systolic heart failure (2).
In summary, the complete characterization of AS
includes disease severity, progression, and manage-
ment, the emphasis being the disease not just the
valve (Figure 1). TAVR is a ground-breaking advance
in the treatment of AS, which is now applicable to
patients with severe AS at low-risk for surgery.
Therefore, it behooves us to open our eyes, ears, and
minds and continue to make strides in the effective
and timely management of the significant public
health problem that is AS. It is worth remembering
the words of C.S. Lewis: “What you see and what
you hear depends a great deal on where you are
standing” (13).
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